Clinical Trials Directory

Trials / Unknown

UnknownNCT03178929

Effect of SAMe Treatment on Recurrence After Radical Treatment of Primary Hepatic Carcinoma

A Randomized Controlled Study on the Effect of S-Adenosyl Methionine Treatment on Anti-tumor Recurrence After Radical Treatment of Primary Hepatic Carcinoma

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
207 (estimated)
Sponsor
Beijing Insight Science & Technology Co. Ltd. · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The aim of this study is to explore the effect of SAMe on recurrence after radical treatment of Primary liver cancer.

Detailed description

Primary liver cancer is now a major health problem. In the worldwide, PLC is the fifth most common cancer in male, the seventh in female, and has the second highest rate to cause death for men . Although the recent advances in treatment of Primary liver cancer have significantly improved the prognosis of patients with Primary liver cancer, the overall survival rate is still unsatisfactory. One of the reasons for the poor prognosis of Primary liver cancer is its high rate of recurrence. Anti-relapse treatment remains a pressing work to do. In recent years, some study reported that SAMe had an impact on promoting apoptosis and inhibiting the growth on breast cancer, colon cancer, gastric cancer and liver cancer in vitro and vivo. In this study, we aim to examine whether SAMe have an effect on improving patients' recurrence after radical treatment of Primary liver cancer.

Conditions

Interventions

TypeNameDescription
DRUGS-Adenosyl Methionine2000mg, po

Timeline

Start date
2017-07-01
Primary completion
2020-07-01
Completion
2020-08-31
First posted
2017-06-07
Last updated
2017-06-07

Source: ClinicalTrials.gov record NCT03178929. Inclusion in this directory is not an endorsement.